SynthesisFrontiers in oncology2026
Clinical and prognostic implications of pituitary tumor-transforming gene 1 in solid tumors.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pituitary tumor-transforming 1 (PTTG1) plays a crucial role in cancer pathogenesis and has been associated with survival outcomes and clinicopathological features in patients with various tumors. Therefore, we conducted a comprehensive meta-analysis to evaluate the prognostic and clinicopathological significance of PTTG1 expression in solid tumors. Methods: A comprehensive search of the PubMed, EMBASE and Web of Science was performed to identify eligible studies until July 20, 2025. The hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. Stata SE 12.0 software was used to perform the meta-analysis. Results: 22 studies from 21 articles were included in this meta-analysis. The pooled results showed that patients with high PTTG1 expression had poorer overall survival (OS)(HR:1.85,95%CI:1.55-2.20) and disease-free survival/recurrence-free survival (DFS/RFS) (HR:3.48, 95%CI:1.81-6.70). Subgroup analysis showed that high PTTG1 expression was mainly associated with worse OS in renal cell carcinoma(RCC),non-small cell lung cancer(NSCLC),breast cancer(BC), esophageal squamous cell carcinoma(ESCC) and laryngeal cancer(LRGC). Furthermore, high PTTG1 expression was significantly associated with tumor stage (III-IV vs I-II), T stage (T3-4 vs T1-2), lymphatic invasion(Yes vs No) and metastasis (Yes vs No). Conclusion: PTTG1 may serve as a prognostic indicator in specific cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.